Literature DB >> 24513602

Management of euvolemic hyponatremia attributed to SIADH in the hospital setting.

A Peri1, C Giuliani.   

Abstract

Hyponatremia is the most frequent electrolyte disorder in hospitalized patients. Acute and severe hyponatremia can be a life-threatening condition, but recent evidence indicates that also mild and chronic hyponatremia is associated with neurological and extra-neurological signs, such as gait disturbances, attention deficits, falls and fracture occurrence, and bone loss. The syndrome of inappropriate ADH secretion (SIADH) is the most frequent cause of hyponatremia. Hyponatremia secondary to SIADH may result for instance from ectopic release of ADH in lung cancer, from diseases affecting the central nervous system, from pneumonia or other pneumopathies or as a side-effect of various drugs In SIADH, hyponatremia results from a pure disorder of water handling by the kidney, whereas external sodium balance is usually well regulated. Despite increased total body water, only minor changes of urine output and modest oedema are usually seen. Neurological impairment may range from subclinical to life-threatening, depending on the degree and mostly on the rate of serum sodium reduction. The management of hyponatremia secondary to SIADH is largely dependent on the symptomatology of the patient. This review briefly summarizes the main aspects related to hyponatremia and then discusses the available treatment options for the management of SIADH, including vaptans, which are vasopressin receptor antagonists targeted for the correction of euvolemic hyponatremia, such as that observed in SIADH.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24513602

Source DB:  PubMed          Journal:  Minerva Endocrinol        ISSN: 0391-1977            Impact factor:   2.184


  7 in total

Review 1.  Impact of perioperative hyponatremia in children: A narrative review.

Authors:  Cheme Andersen; Arash Afshari
Journal:  World J Crit Care Med       Date:  2014-11-04

Review 2.  SIAD: practical recommendations for diagnosis and management.

Authors:  M Cuesta; A Garrahy; C J Thompson
Journal:  J Endocrinol Invest       Date:  2016-04-19       Impact factor: 4.256

3.  Be aware of the effects of glucocorticoids on SIADH: A case report.

Authors:  Huaqian Li; Lijun Huang; Ge Wu; Xianmei Chen; Qiaoan Zheng; Faming Su; Maoshan Liang; Xiaoming Chen
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

4.  Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma.

Authors:  N O'Connor-Byrne; S Glavey; R Tudor; P Murphy; C J Thompson; J Quinn
Journal:  Exp Hematol Oncol       Date:  2019-02-01

Review 5.  A narrative review of progress in diagnosis and treatment of small cell lung cancer patients with hyponatremia.

Authors:  Ranpu Wu; Chuling Li; Zimu Wang; Hang Fan; Yong Song; Hongbing Liu
Journal:  Transl Lung Cancer Res       Date:  2020-12

Review 6.  Role of tolvaptan in the management of hyponatremia in patients with lung and other cancers: current data and future perspectives.

Authors:  Bijin Thajudeen; Abdulla K Salahudeen
Journal:  Cancer Manag Res       Date:  2016-08-22       Impact factor: 3.989

Review 7.  Inappropriate Antidiuretic Hormone Secretion and Cerebral Salt-Wasting Syndromes in Neurological Patients.

Authors:  Haiying Cui; Guangyu He; Shuo Yang; You Lv; Zongmiao Jiang; Xiaokun Gang; Guixia Wang
Journal:  Front Neurosci       Date:  2019-11-08       Impact factor: 4.677

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.